- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 35/545 - Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
Patent holdings for IPC class A61K 35/545
Total number of patents in this class: 1249
10-year publication summary
|
73
|
109
|
97
|
148
|
142
|
116
|
134
|
118
|
132
|
38
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 18943 |
38 |
| Kyoto University | 2732 |
30 |
| Tohoku University | 2526 |
29 |
| Life Science Institute, Inc | 70 |
28 |
| FATE Therapeutics, Inc. | 176 |
23 |
| Osaka University | 3143 |
17 |
| President and Fellows of Harvard College | 5792 |
15 |
| Sumitomo Pharma Co., Ltd. | 626 |
14 |
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
13 |
| CRISPR Therapeutics AG | 361 |
13 |
| Memorial Sloan-Kettering Cancer Center | 1789 |
12 |
| Riken | 1669 |
12 |
| ABT Holding Company | 109 |
10 |
| Sumitomo Dainippon Pharma Co., Ltd. | 226 |
10 |
| University of Washington | 2157 |
10 |
| Sumitomo Chemical Company, Limited | 8808 |
9 |
| The Johns Hopkins University | 5377 |
9 |
| CorMatrix Cardiovascular, Inc. | 176 |
9 |
| Minovia Therapeutics Ltd. | 47 |
9 |
| ViaCyte, Inc. | 183 |
9 |
| Other owners | 930 |